Image

Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients

Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

The goal of this prospective cohort study is to investigate the relationship between the TyG index and early identification of MVO in AMI patients undergoing emergency PCI and CMR imaging. The study will enroll approximately 300 AMI patients treated at Xiangya Third Hospital of Central South University from June 2024 to August 2025. The main questions it aims to answer are:

  • How does the TyG index correlate with the early detection of MVO?
  • What differences in cardiovascular adverse events during hospitalization exist between groups with varying TyG index levels? Participants will undergo emergency PCI and CMR imaging within 3-7 days post-procedure. Data collected will include demographic characteristics, clinical history, coronary angiography data, laboratory test indicators (especially metabolic markers such as blood glucose and lipids), IVUS-related plaque information, and CMR results.

Eligibility

Inclusion Criteria:

  • Age ≥ 18 years.
  • STEMI symptom onset time < 12 hours.
  • STEMI symptom onset time 12-48 hours, with ongoing ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias.
  • Very high-risk NSTEMI; undergoing emergency PCI treatment.
  • Voluntary signed informed consent form.

Exclusion Criteria:

  • Non-obstructive acute myocardial infarction.
  • Severe chronic kidney disease (defined as estimated glomerular filtration rate <20 mL/min per 1.73 m²).
  • Pregnant women or those planning to become pregnant.
  • Failure of emergency PCI.
  • Unclear CMR images

Study details
    Acute Myocardial Infarction (AMI)

NCT07042321

The Third Xiangya Hospital of Central South University

21 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.